Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same

ABSTRACT

An anti-CD3 antibody and a pharmaceutical composition, and their uses are disclosed. The anti-CD3 antibody are useful for treating or preventing cancer. The antibody has high affinity and specificity for CD3 and thus can be effectively used in cancer prevention or treatment.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a Divisional Application of U.S. application Ser.No. 16/754,431 filed Apr. 8, 2020 (allowed), which is National Stage ofInternational Application No. PCT/KR2018/012492 filed Oct. 22, 2018,claiming priority based on Korean Patent Application No. 10-2017-0136564filed Oct. 20, 2017.

SEQUENCE LISTING

The content of the electronically submitted sequence listing, file name:Q280010_Sequence_Listing_As_Filed.xml; size: 47,103 bytes; and date ofcreation: Oct. 3, 2022, filed herewith, is incorporated herein byreference in its entirety.

TECHNICAL FIELD

The present invention relates to an anti-CD3 antibody and apharmaceutical composition for treating cancer comprising same.

BACKGROUND ART

Among various causes of death, death from cancer occurs frequently,accounting for the second-largest proportion. Various attempts have beenmade to treat cancer in the past. Currently, regarding treatment methodsfor treating cancer, administration of an anticancer agent, irradiation,or surgical operation has been carried out. However, such treatmentmethods may be effective in the early stages of cancer, and have a poortherapeutic effect in a terminal cancer, when cancer has spread to othertissues, or when cancer has recurred.

In recent years, attention has been drawn to studies on adoptivecellular immunotherapy in which cancer is treated by subjectinglymphocytes taken from the peripheral blood of a patient to in vitromass culture and then re-transplanting the cultured lymphocytes into thepatient. Furthermore, a technique is also being developed in which toxicT cells specific for cancer cells are allowed to remove cancer cells bysubjecting immune cells taken from the peripheral blood of a patient toin vitro mass proliferation, subjecting the proliferated immune cells totreatment with antigens such as cancer cell lysates so that the immunecells are activated, and then re-administering the resulting immunecells to the patient.

Technical Problem

The present invention is made to solve the above-mentioned problems ofthe prior art. An object of the present invention is to provide anantibody having high binding affinity to CD3 and a pharmaceuticalcomposition having excellent cancer treatment efficacy using the same.

However, the problem to be solved by the present invention is notlimited to the above-mentioned problems, and other problems which arenot mentioned will be clearly understood by those skilled in the artfrom the following description.

Solution to Problem

In an aspect of the present invention, there is provided an antibody,comprising a light chain variable domain (VL domain) consisting of asequence having at least 80% identity to an amino acid sequence of SEQID NO: 7, 8, 15, or 16 and a heavy chain variable domain (VH domain)consisting of a sequence having at least 80% identity to an amino acidsequence of any one of SEQ ID NOs: 18 to 25.

In another aspect of the present invention, there is provided apolynucleotide that encodes the light chain variable domain (VL domain)and the heavy chain variable domain (VH domain) of the antibody.

In yet another aspect of the present invention, there is provided anexpression vector comprising the polynucleotide.

In still yet another aspect of the present invention, there is provideda host cell transformed with the expression vector.

In still yet another aspect of the present invention, there is provideda method for producing an antibody that specifically binds to CD3,comprising culturing the host cell.

In still yet another aspect of the present invention, there is provideda pharmaceutical composition for preventing or treating cancer,comprising the antibody or a fragment thereof.

Advantageous Effects of Invention

Owing to high affinity and specificity to CD3, an antibody of thepresent invention can be effectively used for prevention or treatment ofcancer.

It is to be understood that the effect of the present invention is notlimited to the above-described effects, and includes all effects thatare deducible from the configuration of the invention described in thedetailed description or the claims of the present invention.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 illustrates results obtained by analyzing binding affinity tohuman T cells of antibodies according to an embodiment of the presentinvention.

FIG. 2 illustrates results obtained by analyzing binding affinity tomonkey T cells of antibodies according to an embodiment of the presentinvention.

DETAILED DESCRIPTION OF INVENTION

Hereinafter, the present invention will be described in detail.

In an aspect of the present invention, there is provided an antibodycomprising a light chain variable domain (VL domain) consisting of asequence having at least 80% identity to an amino acid sequence of SEQID NO: 7, 8, 15, or 16 and a heavy chain variable domain (VH domain)consisting of a sequence having at least 80% identity to an amino acidsequence of any one of SEQ ID NOs: 18 to 25.

The light chain variable domain may consist of an amino acid sequencehaving at least 80%, preferably at least 90%, more preferably at least95%, and most preferably at least 99% identity to an amino acid sequenceof SEQ ID NO: 7, 8, 15, or 16.

In addition, the heavy chain variable domain may consist of an aminoacid sequence having at least 80%, preferably at least 90%, morepreferably at least 95%, and most preferably at least 99% identity to anamino acid sequence of any one of SEQ ID NOs: 18 to 25.

The antibody comprising the light chain variable domain and the heavychain variable domain may specifically bind to cluster ofdifferentiation 3 (CD3). Here, the antibody may have cross-reactivity tohuman and monkey CD3. That is, the CD3 may include, but is not limitedto, human-derived CD3 and monkey-derived CD3.

As used herein, the term “CD3” may refer to a concept that collectivelyrefers to CD3 itself, and any variant, isotype, and paralog thereof,which are present in an animal and preferably in a human and a monkey.In addition, as used herein, the term “human CD3” refers tohuman-derived CD3. As used herein, the term “monkey CD3” refers tomonkey-derived CD3.

As used herein, the term “antibody” refers to an immunoglobulin (Ig)molecule that is immunologically reactive with a particular antigen,that is, a protein molecule that acts as a receptor that specificallyrecognizes an antigen. In addition, the antibody may be a whole antibodyor an antibody fragment.

In the light and heavy chain variable domains, some amino acids may besubstituted, inserted, and/or deleted as long as properties consistentwith the object of the present invention, such as affinity andspecificity to CD3, are maintained. For example, conservativesubstitutions of amino acids may occur in the light and/or heavy chainvariable domains. The conservative substitution means a substitution ofan original amino acid sequence with another amino acid residue havingproperties similar thereto.

For example, lysine, arginine, and histidine have similar properties inthat they have a basic side chain, and aspartic acid and glutamic acidhave similar properties in that they have an acidic side chain. Inaddition, glycine, asparagine, glutamine, serine, threonine, tyrosine,cysteine, and tryptophan have similar properties in that they have anon-charged polar side chain; alanine, valine, leucine, threonine,isoleucine, proline, phenylalanine, and methionine have similarproperties in that they have a nonpolar side chain; and tyrosine,phenylalanine, tryptophan, and histidine have similar properties in thatthey have an aromatic side chain.

Therefore, it is apparent to those skilled in the art that the aminoacid substitutions within the group of the amino acids having similarproperties as described above will not cause any significant change inthe properties. For this reason, antibodies that have undergonevariation caused by a conservative substitution within the variabledomain are also included in the scope of the present invention as longas such antibodies maintain properties of the antibody of the presentinvention.

On the other hand, the antibody may specifically bind to T cells,specifically to the surface of T cells, through specific binding withCD3. Here, the T cells may include, but are not limited to,human-derived T cells and monkey-derived T cells.

That is, when the antibody is present in the body, such an antibody mayattract T cells through specific binding with CD3. Accordingly, theattracted T cells may induce immune responses in the vicinity thereof,and may further attack tumors such as cancer cells, and the like.

The light and heavy chain variable domains of the antibody may consistof complementarity determining regions (CDRs) and framework regions(FRs).

Typically, CDRs provide binding specificity to specific antigens, andFRs function to form the antibody's folded structure, to support bindingof CDRs, or the like.

The antibody may be an antibody that retains CDRs of the existing mouseanti-CD3 antibody, SP34, in which the amino acids of the constant domain(Fc) and the variable domain's FRs of SP34 are partially or entirelysubstituted with their human counterparts.

The antibody may comprise a light chain CDR1 including the amino acidsequence of SEQ ID NO: 29; a light chain CDR2 including the amino acidsequence of SEQ ID NO: 30; a light chain CDR3 including the amino acidsequence of SEQ ID NO: 31; a heavy chain CDR1 including the amino acidsequence of SEQ ID NO: 32; a heavy chain CDR2 including the amino acidsequence of SEQ ID NO: 33; and a heavy chain CDR3 including the aminoacid sequence of SEQ ID NO: 34.

Accordingly, the antibody may be a humanized antibody that specificallybinds to human CD3. As used herein, the term “humanized antibody” refersto a chimeric antibody that contains a minimal sequence derived from animmunoglobulin of a non-human antibody, such as a mouse antibody, andmay mean such an antibody in which all parts except a sequencecorresponding to a hypervariable region are substituted with their humancounterparts.

In addition, the term “hypervariable region (HVR)” refers to a region ofa variable domain which exhibits hypervariability or forms astructurally defined loop in the sequence of an antibody. Amongdefinitions identifying the same, the complementarity determining region(CDR) definition according to Kabat is most commonly used to classifyregions based on sequence variability.

For the antibody, an antibody fragment thereof may also be used as longas the antibody fragment maintains the antibody's function. The antibodyor antibody fragment may include, but is not limited to, single-chainantibodies, diabodies, triabodies, tetrabodies, Fab fragments, F(ab′)2fragments, Fd's, scFv's, domain antibodies, minibodies, scAb's, IgDantibodies, IgE antibodies, IgM antibodies, IgG1 antibodies, IgG2antibodies, IgG3 antibodies, IgG4 antibodies, derivatives of antibody'sconstant domains, artificial antibodies based on protein scaffolds, andthe like, which maintain a binding function to CD3.

Meanwhile, the antibody may also be used in the form of an antibody-drugconjugate (ADC) obtained by binding of the antibody with an anticancerdrug having tumor-cell proliferation inhibition efficacy. As usedherein, the term “anticancer” includes “prevention” and “treatment”effects on cancer, and the “prevention” means any act of inhibiting ordelaying cancer. In addition, the “treatment” means any act ofameliorating or beneficially altering symptoms of cancer.

The drug that can be used in the antibody-drug conjugate includes anycompound having a cytotoxic or cytostatic effect, and a part orfunctional group of the compound. Examples of the drug includemicrotubulin structure formation inhibitors, meiosis inhibitors, RNApolymerase inhibitors, topoisomerase inhibitors, DNA intercalators, DNAalkylators, ribosomal inhibitors, miRNAs, shRNAs, siRNAs, radioisotopes,and toxins, among which at least one compound may be used.

The drug may include, but is not limited to, maytansinoid, auristatin,dolastatin, trichothecene, CC1065 (NSC 298223), calicheamicin, taxane,anthracycline, methotrexate, adriamycin, vindesine, vinca alkaloids(vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycinC, chlorambucil, daunorubicin, daunomycin, etoposide, teniposide,carminomycin, aminopterin, dactinomycin, mitomycins, bleomycins,esperamicins, other enediyne antibiotics, 5-fluorouracil, other nitrogenmustards and stereoisomers, isosteres, homologs, or derivatives thereof,cis-platinum and cis-platinum homologs, other intercalator enzymes andfragments thereof, for example, nucleases, antibiotics, toxins(enzymatically active toxins or small molecule toxins of bacterial,fungal, plant, or animal origin), and various antitumor or anticanceragents such as cisplatin, CPT-11, paclitaxel, and docetaxel.

In addition, the radioisotope (radionuclide) includes 3H, 14C, 32P, 35S,36C1, 51Cr, 57Co, 58Co, 59Fe, 90Y, 1251, 1311, 186Re, and the like.MicroRNAs (miRNAs), siRNAs, shRNAs, and the like may also be used whichcan inhibit expression of certain oncogenes.

Binding of the anti-CD3 antibody with a drug is preferably achieved byconjugation using a functional group such as a thiol group of an aminoacid residue such as lysine or cysteine in the antibody. If necessary,it is also possible to perform conjugation in a linker-mediated formwhich is commonly used. A maleimide- or iodine acetamide-based linkermay also be used.

When a drug is conjugated to the antibody or a fragment thereof, thedrug may be conjugated to the C-terminal site, which is opposite to anantigen binding site, from the viewpoint of decreasing an effect on theantibody or fragment's binding capacity and specificity to CD3, and thelike. When the whole antibody, rather than a fragment thereof, is used,the drug may be conjugated to an Fc region.

In addition, the antibody may also be used as a chimeric antigenreceptor (CAR)-based therapeutic agent containing the same. Examples ofsuch a therapeutic agent preferably include, but are not limited to,chimeric antigen receptor T cell (CAR-T cell) or chimeric antigenreceptor natural killer cell (CAR-NK cell) therapeutics.

The antibody may also be used in the form of a bispecific antibodycontaining an anti-CD3 antibody. The bispecific antibody is an antibodythat has capacity of binding to two antigens at the same time, and maytypically exist in a form in which heavy and light chain pairs that bindto different antigens are linked to each other.

In addition, the bispecific antibody is available in a form such as abispecific single-chain antibody where single-chain antibody fragments(scFv's), in which VL and VH are linked to each other via a short linkerpeptide, are connected in the form of scFv1-scFv2(-Fc), a single-domainantibody (sdAb)-based dual antibody using VH, and a bispecific antibodygenerated using BiTE technology (see http://www.micromet.de) fromMicromet, Germany.

The bispecific antibody may exist in a form in which the anti-CD3antibody is bound to an antibody or a fragment thereof having bindingcapacity to an immunopotent cell-specific target molecule. Theimmunopotent cell-specific target molecule may preferably be selectedfrom, but is not limited to, TCR/CD3, CD16 (FcγRIIIa), CD44, CD56, CD69,CD64 (FcγRI), CD89, and CD11b/CD18 (CR3).

In another aspect of the present invention, there is provided apolynucleotide that encodes the light chain variable domain (VL domain)and the heavy chain variable domain (VH domain) of the antibodyaccording to the present invention and an expression vector comprisingthe same.

The polynucleotide that encodes the heavy chain variable domain of theantibody or an antibody fragment, that is, gene, may be easily derivedby those skilled in the art from the amino acid sequence of the anti-CD3antibody.

As used herein, the term “expression vector” refers to a recombinantvector capable of expressing a target protein in a host cell, and meansa gene construct that contains essential regulatory elements operablylinked thereto so that an inserted gene is expressed. The gene encodingthe anti-CD3 antibody may be inserted into a separate vector or may beused in a form of being inserted into the same vector.

Specifically, the polynucleotide that encodes the amino acid sequence ofthe anti-CD3 antibody may be used in a form of being inserted into aseparate or the same vector, and the polynucleotide that encodes theheavy chain or a variable domain thereof may be used in a form of beinginserted into a separate or the same vector.

As used herein, the term “operably linked” means that a nucleic acidexpression regulatory sequence and a nucleic acid sequence encoding adesired protein are functionally linked to perform a desired function.Operable linkage with a recombinant vector may be achieved using geneticrecombination techniques well known in the art, and site specific DNAcleavage and ligation may be easily achieved using enzymes and the likecommonly known in the art.

Expression vectors suitable for production of the anti-CD3 antibody maycontain signal sequences for membrane targeting or secretion in additionto expression regulatory elements such as promoters, initiation codons,termination codons, polyadenylation signals, and enhancers. Initiationcodons and termination codons are generally considered to be part of anucleotide sequence encoding an immunogenic target protein. Such codonsmust be functional in a subject when a gene construct is administeredand must be in frame with a coding sequence. In general, promoters maybe constitutive or inducible. The promoter may include, but is notlimited to, prokaryotic promoters such as lac, tac, T3, and T7, simianvirus 40 (SV40) promoters, mouse breast tumor virus (MMTV) promoters,human immunodeficiency virus (HIV) promoters, for example, long terminalrepeat (LTR) promoter of HIV, Moloney virus promoters, cytomegalovirus(CMV) promoters, Epstein bar virus (EBV) promoters, Rous sarcoma virus(RSV) promoters, as well as R-actin promoters, human hemoglobin-, humanmuscle creatine-, human metallothionein-derived eukaryotic promoters,and the like.

The expression vector may further contain a selectable marker thatallows for selection of host cells containing the same. The selectablemarker is employed for selecting cells transformed with the vector. Forthe selectable marker, markers may be used which confer a selectablephenotype, such as drug resistance, auxotrophy, resistance to cytotoxicagents, or expression of surface proteins. In an environment treatedwith a selective agent, only cells expressing a selection markersurvive, which allows for selection of transformed cells. In addition,when the vector is a replicable expression vector, such a vector maycontain a replication origin that is a specific nucleic acid sequencefrom which replication is initiated.

As a recombinant expression vector for insertion of a foreign gene,various forms of vectors such as plasmids, viruses, and cosmids may beused. The type of recombinant vector is not particularly limited as longas the vector functions to express a desired gene and produce a desiredprotein in various host cells including prokaryotic and/or eukaryoticcells. The vector may preferably be a vector capable of producing alarge amount of foreign protein that is in a form similar to its naturalstate while having a promoter with strong activity and strong expressioncapacity.

Various expression host/vector combinations may be used to express theanti-CD3 antibody. The expression vector suitable for eukaryotic hostsincludes, but is not limited to, expression regulatory sequences derivedfrom SV40, bovine papillomavirus, adenovirus, adeno-associated virus,cytomegalovirus, and retrovirus. The expression vector that may be usedin bacterial hosts includes bacterial plasmids obtained from Escherichiacoli, such as pET, pRSET, pBluescript, pGEX2T, pUC vector, colE1, pCR1,pBR322, pMB9, and derivatives thereof; plasmids having a wide host rangesuch as RP4; phage DNAs that may be exemplified by a wide variety ofphage lambda derivatives such as λgt10, λgt11, and NM989; and other DNAphages such as M13 and filamentous single-stranded DNA phages. Theexpression vector useful for yeast cells may include 2-micron plasmidsand derivatives thereof. The vector useful for insect cells may bepVL941.

In yet another aspect of the present invention, there is provided a hostcell, transformed with an expression vector according to the presentinvention. The expression vector may be inserted into a host cell toform a transformant. A suitable host cell for the vector may includeprokaryotic cells such as Escherichia coli, Bacillus subtilis,Streptomyces sp., Pseudomonas sp., Proteus mirabilis, or Staphylococcussp. In addition, the host cell may include eukaryotic cells includinglower eukaryotic cells from fungi such as Aspergillus sp., yeasts suchas Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces sp.,and Neurospora crassa, and other lower eukaryotes, and higher eukaryoticcells such as insect cells. In addition, the host cell may also bederived from plants or mammals. Preferably, the host cell that may beused includes, but is not limited to, monkey kidney cells (COS7 cells),NSO cells (myeloma cells of mouse origin), SP2/0 cells (myeloma cells ofmouse origin), other myeloma cell lines, Chinese hamster ovary (CHO)cells, W138 cells (diploid human cell culture), baby hamster kidney(BHK) cells, MDCK, HuT 78 cells, HEK293 cells, and the like, with CHOcells being preferred.

As used herein, the term “transformation into host cells” is intended toinclude any method for introducing a nucleic acid into an organism,cell, tissue, or organ and, and such transformation may be performedusing a standard technique as known in the art selected depending on thetype of host cell. Specifically, electroporation, protoplast fusion,calcium phosphate (CaPO₄) precipitation, calcium chloride (CaCl₂))precipitation, agitation using silicon carbide fiber,agrobacterium-mediated transformation, PEG-, dextran sulfate-,lipofectamine-, or desiccation/inhibition-mediated transformation, orthe like may be used. However, the present invention is not limitedthereto.

In still yet another aspect of the present invention, there is provideda method for producing an antibody that specifically binds to CD3,comprising culturing the host cell. Specifically, the method forproducing an antibody may comprise the steps of: inserting into avector, a nucleotide sequence encoding the anti-CD3 antibody, toconstruct a recombinant vector; transforming a host cell with therecombinant vector and performing culture; and a step of separating andpurifying a humanized antibody from the cultured transformant.

The humanized antibodies may be produced in a large amount by culturingthe transformant, in which the recombinant vector is expressed, in anutrient medium, and the medium and culture conditions may beappropriately selected from those known in the art depending on the typeof host cell. During culture, conditions such as temperature, pH of amedium, and culture time may be appropriately adjusted to be suitablefor cell growth and mass production of a protein.

The recombinantly produced anti-CD3 antibodies as described above may berecovered from a medium or a cell lysate. When the antibody is in amembrane-bound form, such an antibody may be liberated from the membraneusing a suitable surfactant solution (for example, Triton-X 100) or byenzymatic cleavage. Cells used for expression of humanized antibodiesmay be disrupted by various physical and chemical means such asfreeze-thaw cycles, sonication, mechanical disruption, or cell lysisagents, and separation and purification may be performed usingconventional biochemical separation techniques. The biochemicalseparation technique that may be used includes, but is not limited to,electrophoresis, centrifugation, gel filtration, precipitation,dialysis, chromatography (ion-exchange chromatography, affinitychromatography, immunoabsorbent chromatography, size exclusionchromatography, or the like), isoelectric focusing, and the like.

In still yet another aspect of the present invention, there is provideda pharmaceutical composition for preventing or treating cancer,comprising an antibody according to the present invention or a fragmentthereof.

The type of cancer that can be treated with the pharmaceuticalcomposition may include both solid cancer and blood cancer, andpreferably may include any cancers which express CD3. Here, the antibodymay attract T cells through specific binding with CD3, and thus inducedeath of cancer cells.

Specifically, the cancer may be, but is not limited to, pancreaticcancer, liver cancer, gastric cancer, lung cancer, colorectal cancer,rectal cancer, thyroid cancer, esophageal cancer, kidney cancer, bladdercancer, prostate cancer, cervical cancer, breast cancer, blood cancer,skin cancer, epithelial cancer, brain cancer, central nerve systemcancer, or ovarian cancer.

The pharmaceutical composition may further comprise a pharmaceuticallyacceptable carrier. As the pharmaceutically acceptable carrier, abinder, a glidant, a disintegrant, an excipient, a solubilizer, adispersant, a stabilizer, a suspending agent, a pigment, a flavor, andthe like may be used for oral administration; a buffer, a preservingagent, a pain-relieving agent, a solubilizer, an isotonic agent, astabilizer, and the like may be used in admixture for injections; and abase, an excipient, a lubricant, a preserving agent, and the like may beused for topical administration.

Formulations of a pharmaceutical composition of the present inventionmay be prepared in various ways by being mixed with the pharmaceuticallyacceptable carrier as described above. For example, for oraladministration, the pharmaceutical composition may be formulated in theform of tablets, troches, capsules, elixirs, suspensions, syrups,wafers, or the like. For injections, the pharmaceutical composition maybe formulated in the form of unit dosage ampoules or multiple dosageforms.

In addition, the pharmaceutical composition may contain a surfactantthat can improve membrane permeability. These surfactants may be derivedfrom steroids or may include cationic lipids such asN-[1-(2,3-dioleoyl)propyl-N,N,N-trimethylammonium chloride (DOTMA), orvarious compounds such as cholesterol hemisuccinate and phosphatidylglycerol. However, the surfactant is not limited thereto.

In still yet another aspect of the present invention, there is provideda method for treating cancer or inhibiting cancer growth, comprisingadministering the pharmaceutical composition to a subject. Thepharmaceutical composition comprising the anti-CD3 antibody may beadministered in a pharmaceutically effective amount to treat cancercells or metastases thereof or to inhibit cancer growth. The effectiveamount may vary depending on various factors such as type of cancer, thepatient's age, weight, nature and severity of symptoms, type of currenttherapy, number of treatments, dosage form, and route of administration,and may be easily determined by experts in the corresponding field.

The pharmaceutical composition may be administered together orsequentially with the above-mentioned pharmacological or physiologicalcomponents, and may also be administered in combination with additionalconventional therapeutic agents, in which case the pharmaceuticalcomposition may be administered sequentially or simultaneously with theconventional therapeutic agents. Such administration may be single ormultiple administration. Taking all of the above factors intoconsideration, it is important to administer an amount that is a minimumamount and allows the maximum effect to be obtained without sideeffects, and such an amount may be easily determined by those skilled inthe art.

As used herein, the term “subject” refers to a mammal, preferably human,suffering from or at risk of a condition or disease that can bealleviated, inhibited, or treated by administration of thepharmaceutical composition.

As used herein, the term “administration” means introducing apredetermined substance into a subject in any suitable manner, and thepharmaceutical composition may be administered via any route as long asthe route allows the pharmaceutical composition to reach a targettissue. Such an administration method may include, but is not limitedto, intraperitoneal administration, intravenous administration,intramuscular administration, subcutaneous administration, intradermaladministration, oral administration, topical administration, intranasaladministration, pulmonary administration, or rectal administration.Here, in case of being orally administered, from the viewpoint thatproteins are digested, it may be desirable to formulate a compositionfor oral use so that an active agent is coated or the composition isprotected from digestion in the stomach. In addition, the pharmaceuticalcomposition may be administered by any device such that an activeingredient can migrate to its target cell.

In still yet another aspect of the present invention, there is provideda use of the antibody of the present invention for preventing ortreating cancer.

In still yet another aspect of the present invention, there is provideda use of the antibody of the present invention for manufacture of amedicament for preventing or treating cancer.

In still yet another aspect of the present invention, there is provideda method for preventing or treating cancer, comprising administering theantibody of the present invention to a subject.

BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, the present invention will be described in more detail byway of examples. The following examples are described for the purpose ofillustrating the present invention, and the scope of the presentinvention is not limited thereto.

Example 1. Production of Humanized Anti-CD3 Antibody Candidates Example1.1. Selection of Candidate Antibodies for Humanization

The amino acid sequences of the light chain variable domain (VL domain)and heavy chain variable domain (VH domain) of mouse SP34, known as ananti-CD3 antibody, were entered into a web-based database (IgBLAST), andthen the most similar human embryonic antibody sequences were searched.As a result, the highest amino acid sequence similarity was shownbetween the light chain variable region of mouse SP34 and Homo sapiensIGLV7-46*01 (IMGT gene name), and between the heavy chain variabledomain of mouse SP34 and Homo sapiens IGHV3-73*02 (IMGT gene name).

Example 1.2. Humanization of Light Chain Variable Domain

The CDR amino acid sequence of Homo sapiens IGLV7-46*01 (IMGT genename), a human embryonic antibody having a sequence most similar to thelight chain variable domain of SP34, was replaced with the CDR sequenceof mouse SP34, to prepare a partially humanized light chain variabledomain of SP34.

In order to enhance antigen-binding properties of the partiallyhumanized light chain variable domain of SP34, amino acid residues inthe framework region (FR) sequences that are thought to play animportant function in antigen-binding properties were replaced with thesame amino acid residues as mouse SP34. The amino acid sequence of thehumanized light chain variable domain of SP34 thus prepared is shown inTable 1 below.

Referring to Table 1, random modifications were made to the amino acidresidues 38, 48, 51, and 71 of the light chain variable domain of mouseSP34, to prepare a total of 16 humanized light chain variable domains ofSP34. Here, the light chain variable domain of mouse SP34 was used as acontrol for comparison of affinity to a CD3 antigen.

TABLE 1 Amino acid sequence SEQ Variable(Parts in bold indicate light chain ID Clone domainCDR1, CDR2, CDR3 in order) NO 01 LightQAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWFQQKPGQAP 1 chainRTLIYGTNKRAPWTPARFSGSLLGGKAALTLSGAQPEDEAEYYCAL WYSNLWVFGGGTKLTVLG 02Light QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWFQQKPGQAP 2 chainRTLIYGTNKRAPWTPARFSGSLLGDKAALTLSGAQPEDEAEYYCAL WYSNLWVFGGGTKLTVLG 03Light QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWFQQKPGQAP 3 chainRTLIGGTNKRAPWTPARFSGSLLGGKAALTLSGAQPEDEAEYYCAL WYSNLWVFGGGTKLTVLG 04Light QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWFQQKPGQAP 4 chainRTLIGGTNKRAPWTPARFSGSLLGDKAALTLSGAQPEDEAEYYCAL WYSNLWVFGGGTKLTVLG 05Light QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWFQQKPGQAP 5 chainRGLIYGTNKRAPWTPARFSGSLLGGKAALTLSGAQPEDEAEYYCAL WYSNLWVFGGGTKLTVLG 06Light QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWFQQKPGQAP 6 chainRGLIYGTNKRAPWTPARFSGSLLGDKAALTLSGAQPEDEAEYYCAL WYSNLWVFGGGTKLTVLG 07Light QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWFQQKPGQAP 7 chainRGLIGGTNKRAPWTPARFSGSLLGGKAALTLSGAQPEDEAEYYCAL WYSNLWVFGGGTKLTVLG 08Light QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWFQQKPGQAP 8 chainRGLIGGTNKRAPWTPARFSGSLLGDKAALTLSGAQPEDEAEYYCAL WYSNLWVFGGGTKLTVLG 09Light QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAP 9 chainRTLIYGTNKRAPWTPARFSGSLLGGKAALTLSGAQPEDEAEYYCAL WYSNLWVFGGGTKLTVLG 10Light QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAP 10 chainRTLIYGTNKRAPWTPARFSGSLLGDKAALTLSGAQPEDEAEYYCAL WYSNLWVFGGGTKLTVLG 11Light QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAP 11 chainRTLIGGTNKRAPWTPARFSGSLLGGKAALTLSGAQPEDEAEYYCAL WYSNLWVFGGGTKLTVLG 12Light QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAP 12 chainRTLIGGTNKRAPWTPARFSGSLLGDKAALTLSGAQPEDEAEYYCAL WYSNLWVFGGGTKLTVLG 13Light QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAP 13 chainRGLIYGTNKRAPWTPARFSGSLLGGKAALTLSGAQPEDEAEYYCAL WYSNLWVFGGGTKLTVLG 14Light QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAP 14 chainRGLIYGTNKRAPWTPARFSGSLLGDKAALTLSGAQPEDEAEYYCAL WYSNLWVFGGGTKLTVLG 15Light QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAP 15 chainRGLIGGTNKRAPWTPARFSGSLLGGKAALTLSGAQPEDEAEYYCAL WYSNLWVFGGGTKLTVLG 16Light QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAP 16 chainRGLIGGTNKRAPWTPARFSGSLLGDKAALTLSGAQPEDEAEYYCAL WYSNLWVFGGGTKLTVLG SP34Light QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLF 17 chainTGLIGGTNKRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCAL WYSNLWVFGGGTKLTVLG

Example 1.3. Humanization of Heavy Chain Variable Domain

The CDR amino acid sequence of Homo sapiens IGLV3-73*02 (IMGT genename), a human embryonic antibody having a sequence most similar to theheavy chain variable domain of SP34, was replaced with the CDR sequenceof mouse SP34, to prepare a partially humanized heavy chain variabledomain of SP34.

In order to enhance antigen-binding properties of the partiallyhumanized heavy chain variable domain of SP34, amino acid residues inthe framework region (FR) sequences that are thought to play animportant function in antigen-binding properties were replaced with thesame amino acid residues as mouse SP34. The amino acid sequence of thehumanized heavy chain variable domain of SP34 thus prepared is shown inTable 2 below.

Referring to Table 2, random modifications were made to amino acidresidues 49, 78, 79, and 81 of the heavy chain variable domain of mouseSP34, to prepare a total of 8 humanized heavy chain variable domains ofSP34. Here, the heavy chain variable domain of mouse SP34 was used as acontrol for comparison of affinity to a CD3 antigen.

TABLE 2 Amino acid sequence SEQ Clone Variable(Parts in bold indicate heavy chain ID domain CDR1, CDR2, CDR3 in order)NO A Heavy EVQLVESGGGLVQPGGSLKLSCAASGFTFNTYAMNWVRQASGKGL 18 chainEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS B HeavyEVQLVESGGGLVQPGGSLKLSCAASGFTFNTYAMNWVRQASGKGL 19 chainEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS C HeavyEVQLVESGGGLVQPGGSLKLSCAASGFTFNTYAMNWVRQASGKGL 20 chainEWVGRIRSKYNNYATYYADSVKDRFTISRDDSQSTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS D HeavyEVQLVESGGGLVQPGGSLKLSCAASGFTFNTYAMNWVRQASGKGL 21 chainEWVGRIRSKYNNYATYYADSVKDRFTISRDDSQSTLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS E HeavyEVQLVESGGGLVQPGGSLKLSCAASGFTFNTYAMNWVRQASGKGL 22 chainEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS F HeavyEVQLVESGGGLVQPGGSLKLSCAASGFTFNTYAMNWVRQASGKGL 23 chainEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS G HeavyEVQLVESGGGLVQPGGSLKLSCAASGFTFNTYAMNWVRQASGKGL 24 chainEWVARIRSKYNNYATYYADSVKDRFTISRDDSQSTAYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS H HeavyEVQLVESGGGLVQPGGSLKLSCAASGFTFNTYAMNWVRQASGKGL 25 chainEWVARIRSKYNNYATYYADSVKDRFTISRDDSQSTLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS SP34 HeavyEVQLVESGGGLVQPKGSLKLSCAASGFTFNTYAMNWVRQAPGKGL 26 chainEWVARIRSKYNNYATYYADSVKDRFTISRDDSQSILYLQMNNLKTEDTAMYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS

Example 1.4. Cloning of Humanized Anti-CD3 Antibody Candidates

Each of the genes for the 16 light chain variable domains as preparedabove was inserted into pcDNA3.4 animal cell expression vectorcontaining a lambda light chain constant domain (k-CL), and each of thegenes for the 8 heavy chain variable domains was inserted into pcDNA3.4animal cell expression vector containing IgG1 constant domains (CH1,hinge, CH2, CH3).

The respective specific amino acid sequences for the lambda light chainconstant domain and the IgG1 heavy chain constant domain are shown inTable 3 below.

TABLE 3 SEQ Constant ID Clone domain Amino acid sequence NO λ LightQPKANPTVTLFPPSSEELQANKA 27 chain TLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASS YLSLTPEQWKSHRSYSCQVTHEG STVEKTVAPTEC IgG1 HeavyASTKGPSVFPLAPSSKSTSGGTAA 28 chain LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTK VDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQV YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT PPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

Example 1.5. Transfection of Humanized Anti-CD3 Antibody Candidates

Twenty-four hours before transfection, Expi293F cells at a density of2.0×10⁶ cells/ml were passaged with Expi293 medium at 125±10 rpm in ashaking incubator at a condition of 37° C. and 8% CO₂. When transfectionwas performed, the number of cells and cell viability were measured toidentify whether cell viability of 95% or higher was exhibited.

The cells were dispensed at 7.5×10⁷ cells in a 125 mL culture flask, andthen Expi293 medium was added to adjust the final volume to 25 mL (basedon 30 mL). Using Opti-MEM I medium, 30 μg of antibody-expressing vectorwas mixed therewith to a total of 1.5 ml and incubation was performedfor 5 minutes at room temperature. For the antibody vectors, a total of128 humanized SP34 IgG1 antibodies, obtained by combination of theexpression vectors for 8 heavy chain variable domains and the expressionvectors for 16 light chain variable domains, were used. Mouse humanchimeric SP34 IgG1 antibody was used as a control antibody vector. Thespecific antibody combinations are shown in Table 4 below.

TABLE 4 Heavy chain (VH) Clone A B C D E F G H Light 01 A01 B01 C01 D01E01 F01 G01 H01 chain 02 A02 B02 C02 D02 E02 F02 G02 H02 (VL) 03 A03 B03C03 D03 E03 F03 G03 H03 04 A04 B04 C04 D04 E04 F04 G04 H04 05 A05 B05C05 D05 E05 F05 G05 H05 06 A06 B06 C06 D06 E06 F06 G06 H06 07 A07 B07C07 D07 E07 F07 G07 H07 08 A08 B08 C08 D08 E08 F08 G08 H08 09 A09 B09C09 D09 E09 F09 G09 H09 10 A10 B10 C10 D10 E10 F10 G10 H10 11 A11 B11C11 D11 E11 F11 G11 H11 12 A12 B12 C12 D12 E12 F12 G12 H12 13 A13 B13C13 D13 E13 F13 G13 H13 14 A14 B14 C14 D14 E14 F14 G14 H14 15 A15 B15C15 D15 E15 F15 G15 H15 16 A16 B16 C16 D16 E16 F16 G16 H16

Using Opti-MEM I medium, 80 μl of transfection reagent was mixedtherewith to a total of 1.5 ml, and incubation was performed at roomtemperature for 5 minutes. The Opti-MEM I media respectively containingthe vector and the transfection reagent were gently mixed and allowed toreact at room temperature for 20 minutes. Then, the resultant was placedin the flask containing Expi293F cells. Incubation was performed at125±10 rpm for 16 to 20 hours in a shaking incubator at a condition of37° C. and 8% CO₂. Then, 1.5 ml of transfection enhancer I and 150 μl oftransfection enhancer II were added thereto, and incubation wasperformed for 6 days to obtain candidate antibodies.

Example 1.6. Purification of Antibodies

The incubation was centrifuged at 4,000 rpm for 30 minutes, filteredthrough a 0.22 μm filter, and then cell debris was removed to obtain thesupernatant. 0.2 ml of Mabselect Xtra resin was added to a column, andequilibration was performed using Protein A binding buffer in a volumecorresponding to 10 times the resin volume.

Subsequently, the supernatant was loaded onto the column using gravity.After the loading was completed, the column was washed with Protein Abinding buffer in a volume corresponding to 10 times the resin volume.

Subsequently, IgG elution buffer was added to the column and elution wasperformed. The eluate was neutralized by adding 25 μl of 1.5 M Tris-Clper 1 ml of the eluate. Then, the eluate concentration was measured atan OD of 280 nm. The eluant for which the concentration had beenmeasured was subjected to buffer exchange with PBS via dialysis.

Example 2. Selection of Humanized Anti-CD3 Antibodies

Enzyme-linked immunosorbent assay (ELISA) was used to select antibodiesshowing affinity to human CD3 and monkey CD3 among a total of 128anti-CD3 antibody (SP34) combinations.

Specifically, recombinant human or cynomolgus monkey CD3ε/δ heterodimerwas diluted in a coating buffer and used to treat a 96-well-plate. Theplate was stored at 4° C. for 12 hours or longer. Subsequently, thebuffer was removed and treatment with a 1% bovine serum albumin(BSA)/PBS solution was performed at room temperature for 1 hour. Then,the solution was removed. The recombinant CD3-coated wells were thentreated with antibody-expressing culture solutions for about 1 hour.

The wells were washed with a 0.05% Tween 20/PBS solution, and thentreatment with the human IgG antibody conjugated with horseradishperoxidase, which had been diluted in a 1% BSA/PBS solution, wasperformed at room temperature for 1 hour. Then, the solution was removedand the wells were washed with a 0.05% Tween 20/PBS solution.

A TMB (3,3′,5,5′-tetramethylbenzidine) solution was used to treat the96-well-plate, and the 96-well-plate was left to stand at roomtemperature for 30 minutes.

Then, treatment with a stop solution was performed, and the degree ofcolor development was immediately determined at an absorbance wavelengthof 450 nm. Among the humanized SP34 antibody candidates, only thosesamples that developed color were clones that maintained affinity to CD3of the mouse SP34 antibody. The specific results obtained by affinitymeasurement are shown in Table 5 below.

TABLE 5 Absorbance (450 nm) Absorbance (450 nm) human cyno human cynoClone BSA CD3 CD3 Clone BSA CD3 CD3 A01 0.107 0.152 0.098 E01 0.0780.100 0.078 A02 0.071 0.098 0.068 E02 0.077 0.095 0.070 A03 0.092 0.1320.094 E03 0.098 0.134 0.076 A04 0.063 0.098 0.065 E04 0.080 0.087 0.067A05 0.152 0.167 0.141 E05 0.083 0.085 0.068 A06 0.084 0.140 0.108 E060.206 0.112 0.086 A07 0.089 1.315 2.546 E07 0.097 0.109 0.115 A08 0.0940.875 2.339 E08 0.106 0.074 0.099 A09 0.061 0.092 0.050 E09 0.072 0.0960.084 A10 0.077 0.097 0.066 E10 0.064 0.083 0.065 A11 0.072 0.122 0.105E11 0.065 0.098 0.075 A12 0.060 0.097 0.068 E12 0.059 0.088 0.064 A130.098 0.172 0.154 E13 0.085 0.139 0.114 A14 0.082 0.125 0.113 E14 0.0680.105 0.078 A15 0.099 2.785 2.864 E15 0.130 2.411 2.702 A16 0.068 2.5382.799 E16 0.089 2.399 2.736 B01 0.055 0.097 0.071 F01 0.084 0.118 0.086B02 0.059 0.086 0.072 F02 0.062 0.093 0.076 B03 0.071 0.126 0.091 F030.078 0.128 0.101 B04 0.053 0.087 0.059 F04 0.057 0.084 0.069 B05 0.0690.102 0.100 F05 0.066 0.105 0.075 B06 0.077 0.138 0.143 F06 0.079 0.1150.096 B07 0.061 0.718 2.449 F07 0.142 0.133 0.163 B08 0.060 0.424 2.193F08 0.076 0.134 0.180 B09 0.063 0.096 0.099 F09 0.071 0.099 0.084 B100.078 0.098 0.076 F10 0.068 0.118 0.091 B11 0.074 0.132 0.107 F11 0.0710.138 0.104 B12 0.059 0.098 0.072 F12 0.090 0.090 0.077 B13 0.130 0.1690.156 F13 0.076 0.192 0.151 B14 0.078 0.127 0.102 F14 0.071 0.114 0.100B15 0.204 2.709 3.161 F15 0.081 2.489 2.755 B16 0.064 2.370 2.926 F160.066 2.455 2.855 C01 0.128 0.131 0.075 G01 0.080 0.113 0.096 C02 0.1080.099 0.071 G02 0.075 0.146 0.069 C03 0.126 0.140 0.089 G03 0.078 0.0980.088 C04 0.073 0.093 0.067 G04 0.067 0.129 0.063 C05 0.099 0.107 0.128G05 0.079 0.109 0.072 C06 0.080 0.108 0.083 G06 0.095 0.118 0.078 C070.113 0.960 2.604 G07 0.077 0.118 0.316 C08 0.111 0.446 2.178 G08 0.1480.137 0.119 C09 0.083 0.109 0.075 G09 0.083 0.106 0.079 C10 0.066 0.0960.074 G10 0.072 0.099 0.079 C11 0.168 0.288 0.261 G11 0.086 0.104 0.080C12 0.065 0.087 0.065 G12 0.057 0.085 0.065 C13 0.128 0.179 0.179 G130.132 0.265 0.242 C14 0.075 0.107 0.095 G14 0.075 0.105 0.099 C15 0.0982.454 2.813 G15 0.091 2.415 2.694 C16 0.092 2.369 2.802 G16 0.108 2.4822.773 D01 0.124 0.136 0.099 H01 0.087 0.121 0.154 D02 0.056 0.150 0.073H02 0.125 0.111 0.080 D03 0.073 0.159 0.130 H03 0.068 0.113 0.085 D040.083 0.091 0.072 H04 0.055 0.077 0.068 D05 0.061 0.121 0.101 H05 0.0590.078 0.061 D06 0.092 0.136 0.110 H06 0.086 0.134 0.101 D07 0.074 1.1682.393 H07 0.060 0.110 0.090 D08 0.083 0.897 2.532 H08 0.091 0.118 0.136D09 0.083 0.122 0.098 H09 0.085 0.141 0.113 D10 0.076 0.117 0.113 H100.055 0.088 0.077 D11 0.105 0.138 0.134 H11 0.083 0.122 0.142 D12 0.0810.095 0.114 H12 0.060 0.099 0.083 D13 0.314 0.569 0.532 H13 0.083 0.1750.196 D14 0.121 0.149 0.113 H14 0.064 0.096 0.094 D15 0.108 2.529 3.006H15 0.067 2.436 2.836 D16 0.080 2.655 2.872 H16 0.080 2.461 2.873

As can be seen from the results in Table 5 above, it was shown that 24clones, A7, A8, A15, A16, B7, B8, B15, B16, C7, C8, C15, C16, D7, D8,D15, D16, E15, E16, F15, F16, G15, G16, H15, and H16, maintainedaffinity to human CD3 and monkey CD3. Thus, these 24 clones wereselected as humanized anti-CD3 antibodies (SP34).

Example 3. Measurement of Affinity to Recombinant CD3 of HumanizedAnti-CD3 Antibodies

The Octet system was used to measure affinity to recombinant CD3 of thehumanized anti-CD3 antibodies (SP34) selected in accordance with Example2.

Specifically, recombinant human or monkey CD3a/6 was prepared at aconcentration of 5 μg/ml in 1×kinetic buffer and used to treat a96-well-plate at 200 μl/well. The CD3ε/δ after treatment was fixed tothe anti-Penta His (HIS1K, Cat #18-5121, Fortebio) sensor.

The clones showing binding affinity to the recombinant human or monkeyCD3ε/δ in the ELISA results were prepared at a concentration of 50 nM in1×kinetic buffer, and treatment therewith was performed at 200 l/well.The 1×kinetic buffer was obtained by diluting 10×kinetic buffer(ForteBio, Cat #18-1092) 10 times with PBS and used.

The interaction between the CD3ε/δ fixed to the sensor and the antibodyat a concentration of 50 nM was analyzed to calculate antigen-antibodyaffinity, and the results are shown in Table 6 below.

TABLE 6 Ag Human CD3E/D Cyno CD3E/D Clone KD (M) kon(1/Ms) kdis(1/s) KD(M) kon(1/Ms) kdis(1/s) cSP34 2.29E−10 2.62E+05 6.01E−05 1.40E−103.78E+05 5.30E−05 A7 1.95E−08 1.19E+05 2.32E−03 2.05E−08 1.53E+053.15E−03 B7 2.14E−08 1.98E+05 4.23E−03 3.09E−08 2.08E+05 6.42E−03 C72.30E−08 1.52E+05 3.49E−03 2.75E−08 1.94E+05 5.35E−03 D7 1.90E−081.13E+05 2.14E−03 2.00E−08 1.43E+05 2.84E−03 A8 2.22E−08 1.02E+052.26E−03 2.19E−08 1.47E+05 3.21E−03 B8 2.76E−08 1.48E+05 4.07E−032.63E−08 1.99E+05 5.25E−03 C8 2.94E−08 1.08E+05 3.17E−03 3.56E−081.66E+05 5.89E−03 D8 3.50E−08 8.20E+04 2.87E−03 2.16E−08 1.23E+052.66E−03 A15 2.96E−10 3.23E+05 9.58E−05 3.64E−10 4.53E+05 1.65E−04 B155.21E−10 3.71E+05 1.93E−04 6.27E−10 5.23E+05 3.28E−04 C15 4.30E−103.76E+05 1.62E−04 6.53E−10 5.25E+05 3.43E−04 D15 2.94E−10 3.27E+059.60E−05 5.33E−10 4.37E+05 2.33E−04 E15 1.74E−09 2.25E+05 3.92E−041.86E−09 2.90E+05 5.40E−04 F15 1.04E−09 1.97E+05 2.06E−04 1.33E−092.24E+05 2.97E−04 G15 1.59E−09 2.09E+05 3.32E−04 1.72E−09 2.69E+054.61E−04 H15 9.53E−10 1.99E+05 1.89E−04 1.17E−09 2.30E+05 2.69E−04 A162.93E−10 2.75E+05 8.07E−05 6.57E−10 3.70E+05 2.43E−04 B16 4.45E−103.22E+05 1.44E−04 6.60E−10 4.66E+05 3.08E−04 C16 4.19E−10 2.68E+051.12E−04 8.88E−10 3.84E+05 3.41E−04 D16 4.46E−10 2.40E+05 1.07E−046.11E−10 3.56E+05 2.17E−04 E16 1.76E−09 1.62E+05 2.84E−04 2.19E−092.20E+05 4.82E−04 F16 8.52E−10 1.41E+05 1.20E−04 1.37E−09 1.85E+052.53E−04 G16 1.32E−09 1.53E+05 2.01E−04 1.75E−09 1.95E+05 3.40E−04 H168.81E−10 1.36E+05 1.20E−04 1.13E−09 1.82E+05 2.06E−04

As can be seen from the results in Table 6, it was identified that allthe clones show excellent affinity to both human and monkey CD3ε/δ; andamong these, Clones A15, B15, C15, D15, A16, B16, C16, and D16 show thebest affinity.

Example 4. Measurement of Affinity to Human T Cells of HumanizedAnti-CD3 Antibodies

Flow cytometry was used to measure affinity to human T cells of thehumanized anti-CD3 antibodies (SP34) selected in accordance with Example2.

Specifically, H9 (ATCC® HTB-176TM) cells were prepared at 2×10⁵ cells in100 μl FACS buffer (1% FBS/FACS sheath) per antibody sample, and then 1μg of antibody was used to treat the cells. The resultant was stored for25 minutes in the dark at 4° C. Subsequently, treatment with 3 ml ofFACS buffer was performed, and centrifugation was performed at 2,000 rpmfor 3 minutes. Then, the supernatant was discarded.

Next, 100 μl FACS buffer containing 1 μg of phycoerythrin(PE)-conjugated human IgG antibody was used to treat the cells, and theresultant was stored for 25 minutes in the dark at 4° C. Subsequently,treatment with 3 ml of FACS buffer was performed, and centrifugation wasperformed at 2,000 rpm for 3 minutes. Then, the supernatant wasdiscarded.

The cells were treated with a 4% formaldehyde solution, stored in thedark at 4° C. for 30 minutes, and then treated with 3 ml of FACS buffer.Centrifugation was performed at 2,000 rpm for 3 minutes, and then thesupernatant was discarded. Treatment with 350 μl of FACS buffer wasperformed, and a flow cytometer was used to perform affinity analysis ofthe antibodies for the human T cells. The analysis results areillustrated in FIG. 1 .

Referring to FIG. 1 , it was found that all antibodies, which had boundto recombinant human CD3ε/δ, also specifically bound to human T cells.

Example 5. Measurement of Affinity to Monkey T Cells of HumanizedAnti-CD3 Antibodies

Flow cytometry was used to measure affinity to monkey T cells of thehumanized anti-CD3 antibodies (SP34) selected in accordance with Example2.

Specifically, monkey splenocytes were prepared at 10⁶ cells in 100 μlFACS solution per antibody sample, and then 1 μg of antibody was used totreat the cells. The resultant was stored for 25 minutes in the dark at4° C. Subsequently, treatment with 3 ml of FACS buffer was performed,and centrifugation was performed at 2,000 rpm for 3 minutes. Then, thesupernatant was discarded.

Next, 100 μl FACS buffer containing 1 μg of PE-conjugated human IgGantibody was used to treat the cells, and the resultant was stored for25 minutes in the dark at 4° C. Subsequently, treatment with 3 ml ofFACS buffer was performed, and centrifugation was performed at 2,000 rpmfor 3 minutes. Then, the supernatant was discarded.

The cells were treated with FITC-conjugated anti-CD20 antibody,PE-Cy5-conjugated anti-CD14, 7-AAD antibody, APC-Cy7-conjugatedanti-CD16 antibody, or V450-conjugated anti-CD45 antibody, and theresultant was stored for 25 minutes in the dark at 4° C. Subsequently,treatment with 3 ml of FACS buffer was performed, and centrifugation wasperformed at 2,000 rpm for 3 minutes. Then, the supernatant wasdiscarded.

The cells were treated with a 4% formaldehyde solution, stored in thedark at 4° C. for 30 minutes, and then treated with 3 ml of FACS buffer.Centrifugation was performed at 2,000 rpm for 3 minutes, and then thesupernatant was discarded. Treatment with 350 μl of FACS buffer wasperformed, and a flow cytometer was used to perform affinity analysis ofthe antibodies for the human T cells. The analysis results areillustrated in FIG. 2 .

Referring to FIG. 2 , it was found that all antibodies, which had boundto recombinant monkey CD3ε/δ, also specifically bound to monkey T cells.

Although the embodiments have been described by a limited number ofexamples and the drawings as described above, it will be apparent tothose skilled in the art that various changes and modifications may bemade without departing from the spirit and scope of the invention. Forexample, it is possible to achieve desired results even in a case wherethe techniques as described are performed in a different order than thedescribed method, and/or the components as described are assembled orcombined in a different form than the described method, or replaced orsubstituted by other components or equivalents.

Therefore, other implementations, other embodiments, and equivalents ofthe appended claims fall within the scope of the appended claims.

1. A method for treating cancer in a subject, comprising administeringan effective amount of an antibody or an antigen-binding fragmentthereof, said antigen or antigen-binding fragment thereof comprising:(a-1) a light chain variable domain (VL domain) comprising the aminoacid sequence of SEQ ID NO: 7 or 8; and (a-2) a heavy chain variabledomain (VH domain) comprising the amino acid sequence of SEQ ID NO: 18,19, 20, or 21, or (b-1) a light chain variable domain (VL domain)comprising the amino acid sequence of SEQ ID NO: 15 or 16; and (b-2) aheavy chain variable domain (VH domain) comprising the amino acidsequence of SEQ ID NO: 18, 19, 20, 21, 22, 23, 24, or 25, wherein the VLdomain of (a-1) and (b-1) comprises complementarity determining region(CDR)1 comprising the amino acid sequence of SEQ ID NO: 29, CDR2comprising the amino acid sequence of SEQ ID NO: 30, and CDR3 comprisingthe amino acid sequence of SEQ ID NO: 31; and wherein the VH domain of(a-2) and (b-2) comprises complementarity determining region (CDR)1comprising the amino acid sequence of SEQ ID NO: 32, CDR2 comprising theamino acid sequence of SEQ ID NO: 33, and CDR3 comprising the amino acidsequence of SEQ ID NO:
 34. 2. The method of claim 1, wherein the canceris pancreatic cancer, liver cancer, gastric cancer, lung cancer,colorectal cancer, rectal cancer, thyroid cancer, esophageal cancer,kidney cancer, bladder cancer, prostate cancer, cervical cancer, breastcancer, blood cancer, skin cancer, epithelial cancer, brain cancer,central nerve system cancer, or ovarian cancer.
 3. The method of claim1, wherein the antibody is a humanized antibody.